Point72 Asset Management
OBIO icon

Point72 Asset Management’s Orchestra BioMed OBIO Stock Holding History

Point72 Asset Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$374K Sell
87,888
-74,058
-46% -$315K ﹤0.01% 3268
2025
Q4 		$672K Buy
+161,946
New +$653K ﹤0.01% 3083

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Point72 Asset Management's OBIO Position: Q1 2026 in Review

Point72 Asset Management reduced its Orchestra BioMed (OBIO) stake by 46% in Q1 2026, selling an estimated $315K and leaving 87,888 shares worth $374K. The position accounts for ﹤0.01% of the portfolio, ranked #3268.

Point72 Asset Management first reported a position in OBIO in Q4 2025 and has held it in 2 quarters since. The position peaked at $672K in Q4 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

  • Point72 Asset Management held 87,888 shares of Orchestra BioMed worth $374K as of Q1 2026.
  • Point72 Asset Management sold 74,058 Orchestra BioMed shares in Q1 2026, an estimated $315K.
  • Orchestra BioMed made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3268 holding.
  • Point72 Asset Management first reported a position in Orchestra BioMed in Q4 2025 and has held it in 2 quarters since.
  • Point72 Asset Management's Orchestra BioMed position peaked at $672K in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.